Advancements in ADHD Care: The Evolving Role of Novel Norepinephrine, Dopamine, and Serotonin Reuptake Inhibition and Nonstimulant Therapies

Program Description

Attention-deficit/hyperactivity disorder (ADHD) affects an estimated 7.1 million US children and 15.5 million US adults, with executive dysfunction, emotional dysregulation, and psychiatric comorbidities contributing to academic, work-related, and social impairment. Stimulants remain the most common treatment, but many patients need or prefer alternatives due to contraindications, comorbidities, tolerability concerns, or misuse risk. Options include established nonstimulant agents, such as atomoxetine, viloxazine, and alpha-2 agonists, as well as a recently approved norepinephrine, dopamine, and serotonin reuptake inhibitor. This webinar reviews the rationale for alternatives to traditional stimulant therapy; the patients most likely to benefit; and the efficacy, safety, and limitations of the evidence for current and new agents, including key considerations for pharmacists selecting, monitoring, and counseling on therapy.

Target audience: Ambulatory Care Pharmacist
Type of activity: Application
Release date: December 7, 2026
Expiration date: February 7, 2026
Time to complete activity: 1 hour
Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, pharmacists will be able to:

• Summarize the incidence and prevalence of attention-deficit/hyperactivity disorder (ADHD), its core clinical features, associated psychiatric and medical comorbidities, and impact on health-related quality of life
• Explain the challenges associated with traditional stimulant therapies for ADHD and the clinical rationale for alternative pharmacotherapy, including patient groups most suited for these agents
• Assess the efficacy, safety, and tolerability of stimulant and nonstimulant ADHD medications and the evolving role of norepinephrine, dopamine, and serotonin reuptake inhibition
• Apply pharmacist-driven strategies for treatment planning, monitoring, and patient counseling to support individualized therapy

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.1 CEU) under the ACPE universal activity number [UAN pending]. The activity is available for CE credit through February 7, 2026.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

has no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Emily Tyler; and Brianna Winters have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms